Specialist Doctor Ahmet Ünsal, M.D.

Career Summary:

• H.S.U. Haseki Training and Research Hospital, Internal Medicine Clinic (Residency Training) / 2014-2019
• Gumushane State Hospital (Specialist) /  2019-2020
• Eyup State Hospital (Specialist) / 2020-2021
• Basaksehir Cam and Sakura City Hospital, Medical Oncology Clinic (Subspecialty Training) / 2021-2024
• Gumushane State Hospital (Specialist - Medical Oncology) / 2024-2026
• Yeditepe University Kosuyolu Hospital (Specialist Physician) / 2026-

Fields of Study:

• Breast cancer
• Lung cancer
• Gastric cancer
• Colon cancer
• Prostate cancer
• Gynecologic cancers
• Immunotherapy
• Targeted therapy

Book Chapters:

• Unsal A. Medulloblastoma. In: Sedef AM, editor. Nadir Tumorler. Ankara: Akademisyen Kitabevi; 2022. p. 133-148. ISBN: 978-625-8259-58-2.
• Unsal A. Paraneoplastic Syndromes Observed in Small Cell Lung Cancer. In: Sedef AM, editor. Paraneoplastik Sendromlar. Ankara: Akademisyen Kitabevi; 2022. p. 229-244. ISBN: 978-625-7679-66-4.
• Unsal A. Novel Anti-Androgen Agents. In: Simsek A, Keskin ET, editors. Her Yonuyle Prostat Kanseri. Ankara: Akademisyen Kitabevi; 2023. p. 267-276. ISBN: 978-625-399-226-2.

Professional Publications:

A- Articles published in international peer-reviewed journals:

• A1. Tunbekici S, Sahin G, Yuksel HC, Unsal A, et al. Real-world comparison of doxorubicin-ifosfamide versus gemcitabine-docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study. Discov Onc. 2025;16:2114. doi:10.1007/s12672-025-03886-1
• A2. Tunbekici S, Sahin G, Yuksel HC, Unsal A, et al. Efficacy and safety of doxorubicin-ifosfamide versus gemcitabine-docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study. Int J Cancer. 2026;158(6):1703-1712. doi:10.1002/ijc.70212
• A3. Majidova N, Yaslikaya S, Mildanoglu MM, Coskun A, Ercan Uzundal D, Sahin TK, Akyildiz A, Akbas S, Camanli U, Sahin E, Atacan H, Bayrakci I, Sakalar T, Mordag Cicek C, Gunenc D, Ilhan N, Unal OU, Alan O, Hamitoglu B, Ozen Engin E, Sever N, Guren AK, Unsal A, Araz M, Erdogan B, Aykan MB, Selcukbiricik F, Guven DC, Ozdemir N, Sahin AB, Bilici A, Kara IO, Yalcin S, Kostek O. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG). Turk J Gastroenterol. 2025;36(5):293-301. doi:10.5152/tjg.2025.24784. PMID: 40241388; PMCID: PMC12070425.
• A4. Tunbekici S, Yuksel HC, Acar C, Sahin G, Orman S, Majidova N, Coskun A, Seyyar M, Dilek MS, Kara M, Disli AK, Demir T, Kolkiran N, Sahbazlar M, Demirciler E, Kus F, Aytac A, Menekse S, Yucel H, Biter S, Koseci T, Unsal A, Ozveren A, Sevinc A, Goker E, Gursoy P. Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study. Cancers (Basel). 2024 Dec 27;17(1):46. doi:10.3390/cancers17010046. PMID: 39796675; PMCID: PMC11718784.
• A5. Kapagan T, Bulut N, Unsal A, Erdem GU. Sorafenib-Associated Bilateral Osteonecrosis of the Femoral Head. Am J Ther. 2024 Sep-Oct 01;31(5):e607-e611. doi:10.1097/MJT.0000000000001751. PMID: 39292845.
• A6. Bulut N, Unsal A, Erdem GU, Simsek A. Diagnostic value of the preoperative platelet/lymphocyte ratio and red cell distribution volume in patients with renal masses. Bratisl Lek Listy. 2023;124(9):685-689. doi:10.4149/BLL_2023_105. PMID: 37635666.
• A7. Ahbab S, Unsal A, Ataoglu HE, Can TS, Kayas D, Savas Y. Prediabetes and Type 2 Diabetes are Independent Risk Factors for Computed Tomography-Estimated Nonalcoholic Fatty Pancreas Disease. Clinics (Sao Paulo). 2019 Oct 28;74:e1337. doi:10.6061/clinics/2019/e1337. PMID: 31664423; PMCID: PMC6807690.

Certificates:

• European Society for Medical Oncology (ESMO) Examination Certificate / 2023, 2024

Actively Performed Professional Duties:

• Medical Oncology Physician, Yeditepe University Kosuyolu Hospital

Memberships:

• Turkish Society of Medical Oncology (TTOD)
• European Society for Medical Oncology (ESMO)